The global infantile spasms therapeutics market size reached US$ 3.6 Billion in 2023. Looking forward, the market is projected to reach US$ 5.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.95% during 2023-2032. The rising prevalence of seizures in infants, increasing health consciousness among the masses resulting in early diagnosis, and the growing number of product approvals and presence of strong pipelines drugs represent some of the key factors driving the market.
Infantile spasms therapeutics refer to the treatment procedures used for treating seizures or an epilepsy syndrome in young children, usually aged between four months and a year of age. An episode of spasm is characterized by the body stiffening suddenly, arms, legs, and head bending forward, the back arching, and short, subtle seizures. Infantile spasm can be caused by brain tumors, birth injuries, infection of the brain, and genetic changes.
There are a number of therapeutic options that are available for infantile spams, including steroids, hormone therapy with corticotropin injection gel and glucocorticoids, as well as antiseizure medications. Infantile spasms therapeutics are more likely to provide sustained results if they are implemented within three weeks after the spasms occur, and treatment can be done by monotherapy or combination therapy. Infantile spasms are diagnosed by physical examination, neurological examination, MRI of the brain, and blood and urine examinations.
However, various factors, such as lesser treatment success rates, high cost of treatment, strict regulations for drug approval, and the augmenting undiagnosed patient pool, are impeding the growth of the infantile spasms therapeutics market. On the contrary, favorable initiatives and programs conducted by the government and private organizations of several countries for promoting awareness regarding the medical condition is creating a positive market outlook.
The market is further driven by the extensive research and development (R&D) activities conducted by the key market players focusing on the development of innovative drugs with higher success rates. Some of the other factors contributing to the market include the expanding healthcare expenditure, rising number of collaborations, partnerships and merger and acquisitions (M&As), rapid urbanization, and inflating disposable income levels.
2. What is the expected growth rate of the global infantile spasms therapeutics market during 2024-2032?
3. What are the key factors driving the global infantile spasms therapeutics market?
4. What has been the impact of COVID-19 on the global infantile spasms therapeutics market?
5. What is the breakup of the global infantile spasms therapeutics market based on the therapeutic class?
6. What is the breakup of the global infantile spasms therapeutics market based on the drug type?
7. What is the breakup of the global infantile spasms therapeutics market based on the dosage?
8. What is the breakup of the global infantile spasms therapeutics market based on route of administration?
9. What is the breakup of the global infantile spasms therapeutics market based on the distribution channel?
10. What is the breakup of the global infantile spasms therapeutics market based on the end user?
11. What are the key regions in the global infantile spasms therapeutics market?
12. Who are the key players/companies in the global infantile spasms therapeutics market?
Infantile spasms therapeutics refer to the treatment procedures used for treating seizures or an epilepsy syndrome in young children, usually aged between four months and a year of age. An episode of spasm is characterized by the body stiffening suddenly, arms, legs, and head bending forward, the back arching, and short, subtle seizures. Infantile spasm can be caused by brain tumors, birth injuries, infection of the brain, and genetic changes.
There are a number of therapeutic options that are available for infantile spams, including steroids, hormone therapy with corticotropin injection gel and glucocorticoids, as well as antiseizure medications. Infantile spasms therapeutics are more likely to provide sustained results if they are implemented within three weeks after the spasms occur, and treatment can be done by monotherapy or combination therapy. Infantile spasms are diagnosed by physical examination, neurological examination, MRI of the brain, and blood and urine examinations.
Infantile Spasms Therapeutics Market Trends
The increasing prevalence of infantile spasms among newborn babies is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the birth rates across the globe. In line with this, the growing number of product approvals and presence of strong pipelines drugs are impacting the market positively. Continual technological advancements in the treatment of infantile spasms, such as the introduction of seizure alert device for detecting seizures and alerting the caregivers, are providing an impetus to the market. Also, the widespread awareness regarding early diagnosis and treatment is enhancing the penetration rate of infantile spasm drugs, thereby fueling the market growth.However, various factors, such as lesser treatment success rates, high cost of treatment, strict regulations for drug approval, and the augmenting undiagnosed patient pool, are impeding the growth of the infantile spasms therapeutics market. On the contrary, favorable initiatives and programs conducted by the government and private organizations of several countries for promoting awareness regarding the medical condition is creating a positive market outlook.
The market is further driven by the extensive research and development (R&D) activities conducted by the key market players focusing on the development of innovative drugs with higher success rates. Some of the other factors contributing to the market include the expanding healthcare expenditure, rising number of collaborations, partnerships and merger and acquisitions (M&As), rapid urbanization, and inflating disposable income levels.
Key Market Segmentation
This report provides an analysis of the key trends in each segment of the global infantile spasms therapeutics market, along with forecasts at the global, regional, and country level from 2024-2032. The report has categorized the market based on therapeutic class, drug type, dosage, route of administration, distribution channel, and end user.Therapeutic Class Insights:
- Anticonvulsants
- Corticosteroids
- Others
Drug Type Insights:
- Vigabatrin
- Adrenocorticotropic Hormone
- Others (Phase III)
Dosage Insights:
- Solid
- Liquid
Route of Administration Insights:
- Oral
- Parenteral
- Others
Distribution Channel Insights:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
End User Insights:
- Hospitals
- Clinics
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global infantile spasms therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report
1. How big is the global infantile spasms therapeutics market?2. What is the expected growth rate of the global infantile spasms therapeutics market during 2024-2032?
3. What are the key factors driving the global infantile spasms therapeutics market?
4. What has been the impact of COVID-19 on the global infantile spasms therapeutics market?
5. What is the breakup of the global infantile spasms therapeutics market based on the therapeutic class?
6. What is the breakup of the global infantile spasms therapeutics market based on the drug type?
7. What is the breakup of the global infantile spasms therapeutics market based on the dosage?
8. What is the breakup of the global infantile spasms therapeutics market based on route of administration?
9. What is the breakup of the global infantile spasms therapeutics market based on the distribution channel?
10. What is the breakup of the global infantile spasms therapeutics market based on the end user?
11. What are the key regions in the global infantile spasms therapeutics market?
12. Who are the key players/companies in the global infantile spasms therapeutics market?
Table of Contents
1 Preface3 Executive Summary14 Value Chain Analysis16 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Infantile Spasms Therapeutics Market
6 Market Breakup by Therapeutic Class
7 Market Breakup by Drug Type
8 Market Breakup by Dosage
9 Market Breakup by Route of Administration
10 Market Breakup by Distribution Channel
11 Market Breakup by End User
12 Market Breakup by Region
13 Drivers, Restraints, and Opportunities
15 Porters Five Forces Analysis
17 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- H. Lundbeck A/S
- Mallinckrodt plc
- ORPHELIA Pharma
- Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.)
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 137 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 3.6 Billion |
| Forecasted Market Value ( USD | $ 5.1 Billion |
| Compound Annual Growth Rate | 3.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 4 |
